Get the Daily Brief
Latest Biotech News
FDA rejection hits Replimune’s melanoma program again
The FDA rejected Replimune’s oncolytic virus therapy RP-1 for advanced melanoma for a second time, according to multiple reports citing the agency’s rationale around unresolved trial doubts. The...
Oricell raises pre-IPO funding to push GPC3 solid-tumor CAR-T
Oricell Therapeutics secured more than $110 million in a pre-IPO round to expand its global footprint and move its lead GPC3-targeted autologous CAR-T therapy toward registrational trials. The...
FDA accepted Telix’s resubmitted brain imaging NDA
The FDA accepted for review Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara, 18F-floretyrosine), a radiolabeled imaging agent intended to characterize progressive or recurrent...
Gilead and Kymera extend protein-degrader bets with KT-200 license
Gilead exercised its option to exclusively license Kymera Therapeutics’ KT-200, an oral CDK2 molecular glue degrader candidate, according to the companies. The move expands Gilead’s oncology...
Roche and C4 Therapeutics sign deal for degrader-antibody conjugates
Roche struck a new collaboration with C4 Therapeutics focused on degrader-antibody conjugates (DACs), pairing C4’s targeted protein degradation platform with Roche’s antibody and ADC delivery...
Biopharma financing and IPO market rebound signals renewed risk appetite
New financing snapshots and broader market coverage point to a strengthening early-2026 fundraising environment for biopharma. Separate reports show Q1 2026 biopharma financings reaching $22.82...
Luminai raises $38M with Cleveland Clinic to automate hospital operations
Luminai raised $38 million in Series B funding to scale its AI platform for automating healthcare administrative workflows, with Cleveland Clinic identified as a key partner for expansion. The...
Oricell and CAR-T expansion continues alongside regulatory uncertainty in melanoma
Carcinoma and oncology finance news continued to dominate the life-science capital flow picture, with Oricell expanding its solid-tumor CAR-T efforts through pre-IPO funding. At the same time,...
Material-to-drug pipeline: new CRISPR/CAR-T adjacent manufacturing and diagnostics signals
Beyond therapeutics, the dataset shows manufacturing and diagnostic infrastructure moves that can affect drug-development throughput. Telix’s FDA acceptance for TLX101-Px is one example of...
FDA and biotech policy signals: PDUFA approach shifts and review mechanics
Policy coverage in the dataset points to a shifting regulatory economics framework for first-in-human (FIH) trials under PDUFA reauthorization. One report says the FDA is moving from punitive fee...
FDA actions: Replimune’s melanoma therapy faces another rejection
The FDA has rejected Replimune Group’s engineered oncolytic virus therapy, RP-1, for advanced melanoma for a second time, escalating scrutiny of the dataset behind the application. The decision...
Capital markets: Oricell raises for solid-tumor CAR-T buildout
Oricell Therapeutics closed a pre-IPO funding round of more than $110 million to accelerate its GPC3-targeted autologous CAR-T for liver cancer, with a pathway toward registrational trials. The...
Regulatory policy: PDUFA shifts toward reward-based ‘America First’
A policy shift would move the U.S. FDA from a punitive first-in-human fee structure toward a reward-based approach under reauthorized PDUFA. The change would reduce certain fees for domestic...
FDA review pipeline: Telix receives acceptance for glioma imaging NDA
The U.S. FDA accepted Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara, 18F-floretyrosine, 18F-FET), a radiolabeled glioma imaging agent used to characterize progressive or recurrent...
Biotech financing: DeepCyte launches with seed funding for single-cell toxicity prediction
DeepCyte launched with $1.5 million in seed funding to commercialize single-cell drug toxicity prediction, betting that single-cell metabolomics can improve how biopharma evaluates safety and...
Drug platform deals: Gilead and Roche expand protein-degrader bets
Gilead exercised its option to exclusively license Kymera Therapeutics’ KT-200, a preclinical oral CDK2 molecular glue degrader, adding a new degrader program to Gilead’s oncology pipeline. The...
Clinical development: Mezagitamab shows platelet gains in Phase 2 ITP trial
Mezagitamab produced clinically meaningful platelet count increases in a Phase 2 trial for immune thrombocytopenia, according to the reported findings. The antibody approach targets the underlying...
Oncology mechanisms: Novel “don’t eat me” signal identified in AML
Researchers from Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute identified a new immune evasion mechanism in acute myeloid leukemia involving CD43, described as a...
Diagnostics & infrastructure: FairJourney Bio opens cryo-EM structural biology facility in San Diego
FairJourney Bio opened a new cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, upgrading its ability to generate atomic-resolution structures directly inside its...
Biopharma funding environment: First-quarter financing rebound and market signals
Biopharma financing rebounded in Q1 2026, with total financings reaching $22.82 billion—about 74% higher than Q1 2025—after a weaker 2025. The figures suggest improved access to capital for...